Sky Eclat
JF-Expert Member
- Oct 17, 2012
- 57,761
- 216,011
Asante sana kwa ushauri. Nilifanya kazi kwenye mradi mmoja wa HIV na magonjwa ya zinaa, kutoka pale nimejenga interest ya kuangalia the up to date research, treatment and cure.
Kumbe Prince ni ngoma iliyomuondoa
Kumbe Prince ni ngoma iliyomuondoa
- Thread starter Maghayo
- Start date
Upiversity
JF-Expert Member
- Jun 19, 2015
- 3,487
- 2,632
...and the good thing unashare na wengine!
....safi sana!
Paula kilaki
JF-Expert Member
- Jun 26, 2014
- 1,909
- 1,290
Mambo Nifah nimekumiss[emoji12]
beefinjector
JF-Expert Member
- Jul 23, 2009
- 2,458
- 2,496
Na wewe alikuambia kwamba ni shoga? Au ndio bla bla zenu?
Sky Eclat
JF-Expert Member
- Oct 17, 2012
- 57,761
- 216,011
A Monthly Shot Could Soon Replace Daily HIV Meds
An injectable combination therapy could replace oral medications and experts think it may improve adherence rates.
By Jacob Anderson-Minshall
NOVEMBER 09 2015 2:12 PM EST
2.1K
SHARES
Injecting HIV drugs every month or two is as effective in suppressing the virus as taking daily medications, according to an eight-month clinical trial reported inPharmabiz and conducted by ViiV Healthcare in collaboration with Janssen Sciences Ireland (one of the Janssen: Pharmaceutical Companies of Johnson & Johnson). Monthly injections could also improve adherence rates by reducing the potential of skipped doses.
"Going from many pills a day — like 10, 20 pills a day — to now one pill, to now one injection every two months is I think a huge medical technical achievement," said Paul Stoffels, Johnson & Johnson’s chairman of pharmaceuticals, in a conference call with reporters. "Despite great progress in HIV treatments, the burden of treating HIV patients remains high. Long-acting injectable drug formulations may offer another option for HIV maintenance therapy."
Just 32-weeks into the 96-week phase 2b trial, known as LATTE 2, researchers were so impressed with results they announced them to the press and are presenting them in an upcoming conference. The study compared a long-acting injectable combination of two separate drugs (cabetogravir and rilpivirine ) with a three-drug daily pill regime (which paired cabotegravir with two nucleoside reverse transcriptase inhibitors).
Once HIV enters T4 white blood cells, the virus uses an enzyme, called reverse transcriptase, to copy parts of its RNA into the cell’s human DNA via a process called "reverse transcription." Rilpivirine blocks that reverse transcription process by binding to and blocking the enzyme. Meanwhile cabetogravir attacks HIV at another point in the virus's lifecycle. After the virus transcribes its RNA into DNA, it then must integrate that DNA into the white blood cell’s DNA. It does this with the help of another enzyme, integrase, which cabetogravir blocks from doing its job.
Patricipants in the clinical trials where either virally suppressed on antiretroviral therapy (ART) or were HIV-positive and not previously on medication (what researchers call “ART-naïve” or "treatment-naïve"). After reaching virologic suppression on oral therapy the patients were subsequently randomized to one of three studies to receive either the injections every 4 or 8 weeks or continue on the oral treatments.
Regardless of frequency of the shots, patients receiving intramuscular injections of the long-acting formulation had viral suppression rates comparable with daily combination therapy. However, patients on monthly injections reported more pain at the injection site then those receiving the shots every two months.
Overall, injection site pain was also the most commonly reported side effect, and it was extreme enough lead a minority of participants to withdraw from the study due to “injection intolerance.”
John C Pottage, Jr., chief scientific and medical officer at ViiV Healthcare focused on the trials' positives, saying, in a written statement, “These initial phase IIb data investigating long-acting cabotegravir and rilpivirine are promising and build on the results we have seen to date. We look forward to seeing further results as we move into phase III.”
As currently formulated, the drug must remain refrigerated and would need to be administered by a medical professional as it requires too large a dose to be prescribed for at-home injections.
Stoffels acknowledged that there is still work to be done. But the pharmaceutical executive highlighted how far the fight against HIV has come since he began his career in Africa. “Back in the late ’80s in Africa when the HIV epidemic was in full growth, it was devastating,” Stoffels recalled.
It may be another five years until it’s available but an injectable, monthly HIV treatment could free people living with HIV from an endless regime of daily pills, while reducing medication fatigue and increasing adherence. Thats a win win to many advocates.
TAGS: TREATMENT
An injectable combination therapy could replace oral medications and experts think it may improve adherence rates.
By Jacob Anderson-Minshall
NOVEMBER 09 2015 2:12 PM EST
2.1K
SHARES
Injecting HIV drugs every month or two is as effective in suppressing the virus as taking daily medications, according to an eight-month clinical trial reported inPharmabiz and conducted by ViiV Healthcare in collaboration with Janssen Sciences Ireland (one of the Janssen: Pharmaceutical Companies of Johnson & Johnson). Monthly injections could also improve adherence rates by reducing the potential of skipped doses.
"Going from many pills a day — like 10, 20 pills a day — to now one pill, to now one injection every two months is I think a huge medical technical achievement," said Paul Stoffels, Johnson & Johnson’s chairman of pharmaceuticals, in a conference call with reporters. "Despite great progress in HIV treatments, the burden of treating HIV patients remains high. Long-acting injectable drug formulations may offer another option for HIV maintenance therapy."
Just 32-weeks into the 96-week phase 2b trial, known as LATTE 2, researchers were so impressed with results they announced them to the press and are presenting them in an upcoming conference. The study compared a long-acting injectable combination of two separate drugs (cabetogravir and rilpivirine ) with a three-drug daily pill regime (which paired cabotegravir with two nucleoside reverse transcriptase inhibitors).
Once HIV enters T4 white blood cells, the virus uses an enzyme, called reverse transcriptase, to copy parts of its RNA into the cell’s human DNA via a process called "reverse transcription." Rilpivirine blocks that reverse transcription process by binding to and blocking the enzyme. Meanwhile cabetogravir attacks HIV at another point in the virus's lifecycle. After the virus transcribes its RNA into DNA, it then must integrate that DNA into the white blood cell’s DNA. It does this with the help of another enzyme, integrase, which cabetogravir blocks from doing its job.
Patricipants in the clinical trials where either virally suppressed on antiretroviral therapy (ART) or were HIV-positive and not previously on medication (what researchers call “ART-naïve” or "treatment-naïve"). After reaching virologic suppression on oral therapy the patients were subsequently randomized to one of three studies to receive either the injections every 4 or 8 weeks or continue on the oral treatments.
Regardless of frequency of the shots, patients receiving intramuscular injections of the long-acting formulation had viral suppression rates comparable with daily combination therapy. However, patients on monthly injections reported more pain at the injection site then those receiving the shots every two months.
Overall, injection site pain was also the most commonly reported side effect, and it was extreme enough lead a minority of participants to withdraw from the study due to “injection intolerance.”
John C Pottage, Jr., chief scientific and medical officer at ViiV Healthcare focused on the trials' positives, saying, in a written statement, “These initial phase IIb data investigating long-acting cabotegravir and rilpivirine are promising and build on the results we have seen to date. We look forward to seeing further results as we move into phase III.”
As currently formulated, the drug must remain refrigerated and would need to be administered by a medical professional as it requires too large a dose to be prescribed for at-home injections.
Stoffels acknowledged that there is still work to be done. But the pharmaceutical executive highlighted how far the fight against HIV has come since he began his career in Africa. “Back in the late ’80s in Africa when the HIV epidemic was in full growth, it was devastating,” Stoffels recalled.
It may be another five years until it’s available but an injectable, monthly HIV treatment could free people living with HIV from an endless regime of daily pills, while reducing medication fatigue and increasing adherence. Thats a win win to many advocates.
TAGS: TREATMENT
Mnondwe
JF-Expert Member
- Apr 10, 2015
- 4,013
- 3,679
Kwa comment hii,tafakari imefanya kazi kwangu!nimejikuta namjua.
Mnondwe
JF-Expert Member
- Apr 10, 2015
- 4,013
- 3,679
Ila taarifa za hili gonjwa zinachanya sana,wengine wanadai amerika ya kaskazini dawa ipo,tena ni single dose,pia taarifa za kufanana zinasema na ulaya pia kwa mataifa tajiri.
Tafakari yangu ni kwanini idaiwe kutumia dawa za kuorefusha maisha,wakati za kutibu zipo!
Sky Eclat
JF-Expert Member
- Oct 17, 2012
- 57,761
- 216,011
Haya mambo ya 'hear say' yameua watu wengi sana, ninadhani taarifa kamili itatoka WHO kama wamepata tiba kamili. Huu ugonjwa umeafect watu wengi sana, na kama dawa itapatikana sidhani kama watu wenye pesa zao watashindwa kujitolea zifike nchi zinazoendelea.
Gang Chomba
JF-Expert Member
- Feb 29, 2008
- 20,649
- 4,786
heh heh heh halagu ukimaliza kupima unapewa Asprin na Cofta....acha kuwazuga wenzio
Loeli
JF-Expert Member
- Jan 26, 2014
- 997
- 763
Kama nyendo zako kingono ni za mashaka ni lazima ukimbie kipimo. Madhara ya kukimbia kipimo wakati unavyo ni makubwa sana. Ukijua una virusi mapema utaanza kujitunza mapema kupitia lishe na ushauri nasaha. Kidonge utachelewa sana kukianza. Ila maamuzi i yako mikononi mwako acha watu waamke wakapime.
mgogoone
JF-Expert Member
- Dec 28, 2015
- 2,900
- 2,099
Kabla hamjaanza kumuhukumu alama & Au Prince.Hilo gazeti la National Enquirer ni La Udaku uliobobea.Habari nyingi za Hilo gazeti ni za majungu Na uzushi.Watu wengi maarufu wamechafuliwa maisha yao Na hilo gazeti.Na wengi wanalishitaki Hilo gazeti.Unafikiri Global publishing kajifunzia wapi UDAKU?
Kwa kifupi hizo habari alikufa Na Ukimwi hazija thibitishwa.
mgogoone
JF-Expert Member
- Dec 28, 2015
- 2,900
- 2,099
mgogoone
JF-Expert Member
- Dec 28, 2015
- 2,900
- 2,099
The Boss ukiangalia picha unaona prince sio mweusi kwa hapa kwetu Bongo.Kwa Watu wanaoishi huko USA kuna sheria ya "one drop "
Hata uwe mweupe kiasi gani kama baba Au mama yako ni mtu mweusi Basi wewe ni mweusi Au "invisible black"
Wako wengi Collin Powell,Smoke Robinson Baraka Obama .................
Huyo atakua hakua mweusi bali alikua ni chotara.
mgogoone
JF-Expert Member
- Dec 28, 2015
- 2,900
- 2,099
Sasa huko USA Chotara haiko kwenye mahesabu ya watu. Mweusi/Mweupe/Asian/Latino Na Wazao (wahindi wekundu)
UncleBen
JF-Expert Member
- Oct 27, 2014
- 9,673
- 12,265
Hee dada mbona iko wazi kabisa hiyo ,kwani ukisema rizimoko sheria ipi itakufunga ? Rizimoko kwetu ni viazi vya mviringo